Incidence of melanoma has been constantly growing during the last decades. Although most
of the new diagnoses are represented by thin melanomas, the number of melanoma-related …

Simple Summary Approximately 50% of patients with melanoma harbor a BRAF mutation
and are eligible for targeted therapy with BRAF/MEK inhibitors (BRAFi/MEKi). Despite a …

Rationale: Metastatic melanoma is the most aggressive and dangerous form of skin cancer.
The introduction of immunotherapy with Immune checkpoint Inhibitors (ICI) and of targeted …

To date, there have been only few studies investigating rechallenge with checkpoint
inhibitors in melanoma patients. Herein, we present the first review of all internationally …

Background Limited treatment outcome data is available for advanced non-small cell lung
cancer (NSCLC) patients with BRAF V600E mutations. In this multicenter study, we describe …

Phenotypic adaptation, the ability of cells to change phenotype in response to external
pressures, has been identified as a driver of drug resistance in cancer. To quantify …

We read with great interest the article by Facchinetti et al.[1] about the molecular
mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E-mutant nonesmall …

Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and
trametinib treatment following immunotherapy Posterior reversible encephalopathy …

Abstract Background: Total saponins from Rubus parvifolius L.(TSRP) are the main bioactive
fractions responsible for the anti-tumor activities. The work was aimed to evaluate the anti …

Figure 1 Pretherapeutic 18F-FDGPET/CT, coronal and sagittal PET reconstruction (date:
06.10. 2020)(a). 18F-FDG-PET/CT with corresponding coronal and sagittal PET …